ESD™: Optimising Antigen Presentation for Faster, Stronger Immunity
Our proprietary Enhanced Surface Display (ESD™) platform modifies how vaccine antigens are processed and presented on the surface of host cells. By bypassing native signals that cause viral antigens to be re-internalised, ESD™ ensures antigens are displayed more rapidly, reach higher densities on the cell surface, and persist for longer durations compared to conventional approaches.
This enhanced presentation translates into significant potential immunological advantages:
Faster Immunity Onset: Quicker triggering of adaptive immune responses.
Stronger Responses: More antigen visible to immune cells may lead to higher antibody titres and stronger T-cell activation.
Potential for Dose Sparing: Achieving protection with lower vaccine doses.
Single Dose Potential: Enhanced priming may enable protection after just one dose.
Improved Durability: Longer antigen display could lead to longer-lasting immunity.